CAR-T 세포치료 시장 예측(-2031년) : 제품별, 표적별, 적응증별, 인구통계별, 최종사용자별, 지역별

The global CAR T-cell therapy market is projected to reach USD 13.78 billion in 2031 from USD 7.24 billion in 2026, at a CAGR of 13.7%. Market growth is primarily driven by rising global cancer prevalence. Technological advancements in CAR T-cell therapies and rising investment and funding for therapy development are likely to propel market growth.

However, adverse effects associated with CAR T-cell therapy and high treatment costs are among the major factors expected to restrain market growth during the forecast period.

"The Yescarta product segment accounted for the largest share by product in the CAR T-cell therapy market in 2025."

Based on product, the CAR T-cell therapy market is broadly segmented into Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Kymriah (tisagenlecleucel), and other products.

The Yescarta segment held the largest market share in 2025. Market growth is driven by high response rates and durable remissions with Yescarta in treating relapsed/refractory cancers, leading to increased therapy adoption.

"The hospitals segment accounted for the largest share by end user segment in the CAR T-cell therapy market in 2025."

Based on end users, the global CAR T-cell therapy market is segmented into hospitals, long-term care facilities, and specialty centers. In 2025, the hospitals segment emerged as the primary growth driver in the global CAR T-cell therapy market, with the highest CAGR during the forecast period.

Hospitals are incorporating CAR T-cell therapies into their standard oncology treatment protocols. This trend is boosting demand for CAR T-cell therapies as more hospitals embrace them. Furthermore, hospitals play a key role in facilitating clinical trials for CAR T-cell therapies. By actively participating in research initiatives and collaborating with pharmaceutical companies and hospitals, the evidence base expands, and regulatory approvals accelerate, which, in turn, stimulate market growth.

"Asia Pacific is projected to grow at the highest CAGR in the CAR T-cell therapy market from 2026 to 2031."

The CAR T-cell therapy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. During the forecast period, Asia Pacific is estimated to grow at the highest CAGR. The supportive regulatory frameworks, rich CAR T-cell therapy product pipeline, and expedited approval processes facilitate quicker market entry for innovative therapies, driving growth in Asia Pacific. In addition, increased collaborations among hospitals, universities, and industries in China are expected to drive robust market growth. The rapid increase in clinical trials evaluating the safety and effectiveness of CAR T-cell therapy across diverse cancer types in China also signals significant advancements. These studies have demonstrated encouraging results in treating leukemia, lymphoma, and solid tumors, with specific patient cohorts showing substantial rates of complete remission and sustained responses. This trend highlights Asia Pacific's progress in developing and validating CAR T-cell therapies, positioning the region as a key player in advancing oncology therapeutic outcomes.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1- 40%, Tier 2- 30%, and Tier 3- 30%
• By Designation: Directors- 20%, Managers- 10%, and Others - 70%,
• By Region: North America -35%, Europe -25%, Asia Pacific -25%, Latin America -10%, and Middle East -5%.

List of Companies Profiled in the Report:

• Bristol-Myers Squibb Company (US)
• Gilead Sciences Inc. (US)
• Novartis AG (Switzerland)
• Johnson & Johnson (US)
• CARsgen Therapeutics Holdings Limited (China)
• IASO Biotherapeutics (China)
• JW (Cayman) Therapeutics Co., Ltd (China)
• ImmunoAct (India)
• CRISPR Therapeutics (Switzerland)
• Autolus Therapeutics (UK)
• Allogene Therapeutics (US)
• Cartesian Therapeutics Inc. (US)
• Guangzhou Bio-gene Technology Co., Ltd (China)
• Wugen (US)

Research Coverage:

This research report categorizes the CAR T-cell therapy market by product (YESCARTA, KYMRIAH, CARVYKTI, ABECMA, TECARTUS, BREYANZI, Other products); by target: CD19, BCMA, other targets; by indication: Multiple myeloma, B-cell lymphoma, Acute lymphoblastic leukemia, Other indications; by demographics: adult, pediatric; by End User: Hospitals, Specialty centers, Long-term care facilities, and by region: North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the CAR T-cell therapy market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, product portfolios, key strategies, such as product launches, collaborations, partnerships, expansions, agreements, and recent developments in the CAR T-cell therapy market. This report provides a competitive analysis of top players and emerging startups in the CAR T-cell therapy market ecosystem.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of revenue for the overall CAR T-cell therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (Technological advancements in CAR T-cell therapies, Label expansions along with strong efficacy signals in hematologic cancers, Growing investments in the development of therapies), restraints (High cost and reimbursement challenges), opportunities (Expanding beyond hematologic malignancies into solid tumors and new disease areas, Focus shift on allogeneic CAR-T and CAR-NK), and challenges (Long-term safety surveillance and evolving labeling requirements) are influencing the growth of CAR T-cell therapy market.

• Product Development/Innovation: Detailed insights on newly launched products of the CAR T-cell therapy market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the CAR T-cell therapy market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CAR T-cell therapy market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Johnson & Johnson (US), JW (Cayman) Therapeutics Co. Ltd (China), ImmunoAct (India), among others in the CAR T-cell therapy market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 CAR T-CELL THERAPY MARKET OVERVIEW
• 3.2 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC AND COUNTRY, 2025
• 3.3 CAR T-CELL THERAPY MARKET: GEOGRAPHIC SNAPSHOT

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Technological advancements in CAR T-cell therapies
    • 4.2.1.2 Label expansions and strong efficacy signals in hematologic cancers
    • 4.2.1.3 Growing investment in CAR T-cell therapy development
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High cost and reimbursement challenges for CAR T-cell therapy
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Expanding beyond hematologic malignancies into solid tumors and new disease areas
    • 4.2.3.2 Focus shift on allogeneic CAR-T and CAR-NK
    • 4.2.3.3 Growing collaborations among biopharmaceutical companies, academic institutions, and research organizations
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Long-term safety surveillance and evolving labeling requirements
• 4.3 UNMET NEEDS & WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
• 4.6 PIPELINE ANALYSIS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 BARGAINING POWER OF SUPPLIERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECASTS
  • 5.2.3 TRENDS IN GLOBAL CAR-T-CELL THERAPY MARKET
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
  • 5.4.1 ROLE IN ECOSYSTEM
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS, BY TYPE, 2025
  • 5.5.2 AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS, BY KEY PLAYER, 2025
  • 5.5.3 AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS, BY REGION, 2025
• 5.6 KEY CONFERENCES & EVENTS, 2026-2027
• 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.8 INVESTMENT/FUNDING SCENARIO
• 5.9 IMPACT OF 2025 US TARIFF ON CAR T-CELL THERAPY MARKET
  • 5.9.1 KEY TARIFF RATES
  • 5.9.2 PRICE IMPACT ANALYSIS
  • 5.9.3 IMPACT ON COUNTRY/REGION
    • 5.9.3.1 North America
      • 5.9.3.1.1 US
    • 5.9.3.2 Europe
    • 5.9.3.3 Asia Pacific
  • 5.9.4 IMPACT ON END-USE INDUSTRIES
    • 5.9.4.1 Hospitals
    • 5.9.4.2 Specialty oncology centers
    • 5.9.4.3 Long-term care facilities

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY TECHNOLOGIES
    • 6.1.1.1 Car design and optimization
    • 6.1.1.2 Viral vector technology
    • 6.1.1.3 Cell culture and expansion techniques
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Gene editing technology (CRISPR-CAS9-based genome editing)
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 Monitoring and imaging technologies
• 6.2 TECHNOLOGY/PRODUCT ROADMAP
• 6.3 FUTURE APPLICATIONS
• 6.4 IMPACT OF AI/GEN AI ON CAR T-CELL THERAPY MARKET

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 REGULATORY FRAMEWORK
  • 7.1.3 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
• 7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
• 7.4 REIMBURSEMENT SCENARIO
• 7.5 COMBINATION THERAPIES

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA, BY END USER
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY

9 CAR T-CELL THERAPY MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 ABECMA
  • 9.2.1 FOCUS ON INCREASED RESEARCH ACTIVITIES FOR INDICATION EXPANSIONS TO DRIVE MARKET
• 9.3 BREYANZI
  • 9.3.1 NEED FOR TREATMENT OF MULTIPLE INDICATIONS TO PROPEL MARKET GROWTH
• 9.4 CARVYKTI
  • 9.4.1 GLOBAL REACH AND SIGNIFICANT REVENUE GROWTH TO SUPPORT MARKET
• 9.5 YESCARTA
  • 9.5.1 FOCUS ON REGULATORY APPROVALS ACROSS MAJOR REGIONS TO BOOST MARKET GROWTH
• 9.6 TECARTUS
  • 9.6.1 EFFORTS TO SECURE REIMBURSEMENT AND IMPROVE MARKET ACCESS FACILITATE PATIENT TO AID MARKET ADOPTION
• 9.7 KYMRIAH
  • 9.7.1 APPROVAL FOR PEDIATRIC USE TO AUGMENT MARKET GROWTH
• 9.8 OTHER PRODUCTS

10 CAR T-CELL THERAPY MARKET, BY TARGET

• 10.1 INTRODUCTION
• 10.2 CD19
  • 10.2.1 RISING INDICATION EXPANSIONS AND NEW APPROVALS TO DRIVE MARKET
• 10.3 BCMA
  • 10.3.1 GROWING PIPELINE PRODUCTS TO PROPEL MARKET GROWTH
• 10.4 CD19/20
  • 10.4.1 DUAL TARGETING TO OFFER COMPETITIVE ADVANTAGE IN ANTIGEN ESCAPE AND TUMOR HETEROGENEITY ISSUES
• 10.5 CD7
  • 10.5.1 ALLOGENEIC CELL SOURCE OF CD7 THERAPIES IN DEVELOPMENT TO SUPPORT GROWTH
• 10.6 OTHER TARGETS

11 CAR T-CELL THERAPY MARKET, BY INDICATION

• 11.1 INTRODUCTION
• 11.2 B-CELL LYMPHOMA (BCL)
  • 11.2.1 RISING PREVALENCE OF B-CELL LYMPHOMAS TO PROPEL MARKET GROWTH
• 11.3 MULTIPLE MYELOMA
  • 11.3.1 GROWING PRODUCT REVENUE AND RISING GLOBAL INCIDENCE OF MYELOMA TO DRIVE MARKET
• 11.4 ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
  • 11.4.1 EXPANDING R&D PIPELINE TO AUGMENT MARKET GROWTH
• 11.5 OTHER INDICATIONS

12 CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC

• 12.1 INTRODUCTION
• 12.2 ADULTS
  • 12.2.1 GROWING PREVALENCE OF HEMATOLOGIC CANCERS TO DRIVE MARKET
• 12.3 PEDIATRIC
  • 12.3.1 HIGH UNMET NEEDS TO LIMIT SEGMENT GROWTH

13 CAR T-CELL THERAPY MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 HOSPITALS
  • 13.2.1 GROWING NEED FOR STANDARD ONCOLOGY TREATMENT PROTOCOLS TO DRIVE MARKET
• 13.3 SPECIALTY CENTRES
  • 13.3.1 NEED FOR OPTIMAL PATIENT CARE AND SPECIALIZED TREATMENT OPTIONS TO SPUR MARKET GROWTH
• 13.4 LONG-TERM CARE FACILITIES
  • 13.4.1 INCREASING INCIDENCE OF CHRONIC DISORDERS AMONG GERIATRIC POPULATION TO PROPEL MARKET GROWTH

14 CAR T-CELL THERAPY MARKET, BY REGION

• 14.1 INTRODUCTION
• 14.2 NORTH AMERICA
  • 14.2.1 US
    • 14.2.1.1 US to dominate CAR T-cell therapy market during study period
  • 14.2.2 CANADA
    • 14.2.2.1 Regulatory approvals and government initiatives for regenerative medicine research to drive market
• 14.3 EUROPE
  • 14.3.1 GERMANY
    • 14.3.1.1 Key product approvals and focus on clinical research to aid market growth
  • 14.3.2 UK
    • 14.3.2.1 Technological advancements in automation and presence of robust research infrastructure to spur market growth
  • 14.3.3 FRANCE
    • 14.3.3.1 Growing focus on cell & gene therapy initiatives to boost market growth
  • 14.3.4 ITALY
    • 14.3.4.1 Growth in biotech sector to augment market growth
  • 14.3.5 SPAIN
    • 14.3.5.1 Rising focus on cell therapies and growing focus on stringent regulations to augment market growth
  • 14.3.6 REST OF EUROPE
• 14.4 ASIA PACIFIC
  • 14.4.1 CHINA
    • 14.4.1.1 Rising number of CAR T-cell clinical trials to fuel market growth
  • 14.4.2 JAPAN
    • 14.4.2.1 Increasing number of product approvals and rising geriatric population to propel market growth
  • 14.4.3 INDIA
    • 14.4.3.1 Growing focus on product commercialization and rising cancer incidence to boost market demand
  • 14.4.4 AUSTRALIA
    • 14.4.4.1 Robust infrastructure for clinical trials and well-developed healthcare sector to aid market growth
  • 14.4.5 SOUTH KOREA
    • 14.4.5.1 Growth in biopharmaceutical industry to facilitate market growth
  • 14.4.6 REST OF ASIA PACIFIC
• 14.5 LATIN AMERICA
  • 14.5.1 BRAZIL
    • 14.5.1.1 Product approvals and high healthcare expenditure to support market growth
  • 14.5.2 REST OF LATIN AMERICA
• 14.6 MIDDLE EAST
  • 14.6.1 GCC COUNTRIES
  • 14.6.2 KINGDOM OF SAUDI ARABIA
    • 14.6.2.1 Increased number of product approvals and high healthcare expenditure to boost market growth
  • 14.6.3 UAE
    • 14.6.3.1 UAE market growth to be driven by localized manufacturing, expanded clinical applications, and strategic collaborations
  • 14.6.4 REST OF MIDDLE EAST
• 14.7 AFRICA
  • 14.7.1 SIGNIFICANT BURDEN OF HEMATOLOGIC MALIGNANCIES AND INFECTIOUS DISEASES TO PROPEL MARKET GROWTH

15 COMPETITIVE LANDSCAPE

• 15.1 INTRODUCTION
• 15.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 15.2.1 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY PLAYERS IN CAR T-CELL THERAPY MARKET
• 15.3 REVENUE ANALYSIS, 2023-2025
• 15.4 MARKET SHARE ANALYSIS, 2025
• 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 15.5.1 STARS
  • 15.5.2 EMERGING LEADERS
  • 15.5.3 PERVASIVE PLAYERS
  • 15.5.4 PARTICIPANTS
  • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 15.5.5.1 Company footprint
    • 15.5.5.2 Region footprint
    • 15.5.5.3 Product footprint
    • 15.5.5.4 Target footprint
    • 15.5.5.5 Indication footprint
• 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 15.6.1 PROGRESSIVE COMPANIES
  • 15.6.2 RESPONSIVE COMPANIES
  • 15.6.3 DYNAMIC COMPANIES
  • 15.6.4 STARTING BLOCKS
  • 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 15.6.5.1 Detailed list of key startups/SMEs
    • 15.6.5.2 Competitive benchmarking of startups/SMEs
• 15.7 COMPANY VALUATION & FINANCIAL METRICS
  • 15.7.1 FINANCIAL METRICS
  • 15.7.2 COMPANY VALUATION
• 15.8 BRAND/PRODUCT COMPARISON
• 15.9 COMPETITIVE SCENARIO
  • 15.9.1 PRODUCT APPROVALS
  • 15.9.2 DEALS
  • 15.9.3 EXPANSIONS
  • 15.9.4 OTHER DEVELOPMENTS

16 COMPANY PROFILES

• 16.1 KEY PLAYERS
  • 16.1.1 JOHNSON & JOHNSON
    • 16.1.1.1 Business overview
    • 16.1.1.2 Products offered
    • 16.1.1.3 Recent developments
      • 16.1.1.3.1 Product approvals
      • 16.1.1.3.2 Deals
    • 16.1.1.4 MnM view
      • 16.1.1.4.1 Key strengths
      • 16.1.1.4.2 Strategic choices
      • 16.1.1.4.3 Weaknesses & competitive threats
  • 16.1.2 GILEAD SCIENCES, INC.
    • 16.1.2.1 Business overview
    • 16.1.2.2 Products offered
    • 16.1.2.3 Recent developments
      • 16.1.2.3.1 Product approvals
      • 16.1.2.3.2 Deals
      • 16.1.2.3.3 Other developments
    • 16.1.2.4 MnM view
      • 16.1.2.4.1 Key strengths
      • 16.1.2.4.2 Strategic choices
      • 16.1.2.4.3 Weaknesses & competitive threats
  • 16.1.3 BRISTOL-MYERS SQUIBB COMPANY
    • 16.1.3.1 Business overview
    • 16.1.3.2 Products offered
    • 16.1.3.3 Recent developments
      • 16.1.3.3.1 Product approvals
      • 16.1.3.3.2 Deals
    • 16.1.3.4 MnM view
      • 16.1.3.4.1 Key strengths
      • 16.1.3.4.2 Strategic choices
      • 16.1.3.4.3 Weaknesses & competitive threats
  • 16.1.4 NOVARTIS AG
    • 16.1.4.1 Business overview
    • 16.1.4.2 Products offered
    • 16.1.4.3 Recent developments
      • 16.1.4.3.1 Product approvals
      • 16.1.4.3.2 Other developments
    • 16.1.4.4 MnM view
      • 16.1.4.4.1 Key strengths
      • 16.1.4.4.2 Strategic choices
      • 16.1.4.4.3 Weaknesses & competitive threats
  • 16.1.5 AUTOLUS THERAPEUTICS
    • 16.1.5.1 Business overview
    • 16.1.5.2 Products offered
    • 16.1.5.3 Recent developments
      • 16.1.5.3.1 Product approvals
      • 16.1.5.3.2 Deals
    • 16.1.5.4 MnM view
      • 16.1.5.4.1 Key strengths
      • 16.1.5.4.2 Strategic choices
      • 16.1.5.4.3 Weaknesses & competitive threats
  • 16.1.6 JW (CAYMAN) THERAPEUTICS CO., LTD.
    • 16.1.6.1 Business overview
    • 16.1.6.2 Products offered
    • 16.1.6.3 Recent developments
      • 16.1.6.3.1 Product approvals
      • 16.1.6.3.2 Deals
  • 16.1.7 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT)
    • 16.1.7.1 Business overview
    • 16.1.7.2 Products offered
    • 16.1.7.3 Recent developments
      • 16.1.7.3.1 Deals
      • 16.1.7.3.2 Other developments
  • 16.1.8 CARSGEN THERAPEUTICS HOLDINGS LIMITED
    • 16.1.8.1 Business overview
    • 16.1.8.2 Products offered
    • 16.1.8.3 Recent developments
      • 16.1.8.3.1 Product approvals
      • 16.1.8.3.2 Deals
      • 16.1.8.3.3 Expansions
  • 16.1.9 IASO BIOTHERAPEUTICS
    • 16.1.9.1 Business overview
    • 16.1.9.2 Products offered
    • 16.1.9.3 Recent developments
      • 16.1.9.3.1 Product approvals
      • 16.1.9.3.2 Deals
  • 16.1.10 IMMUNEEL THERAPEUTICS
    • 16.1.10.1 Business overview
    • 16.1.10.2 Products offered
    • 16.1.10.3 Recent developments
      • 16.1.10.3.1 Product launches
• 16.2 OTHER PLAYERS
  • 16.2.1 WUGEN
  • 16.2.2 CARTESIAN THERAPEUTICS, INC.
  • 16.2.3 ALLOGENE THERAPEUTICS
  • 16.2.4 LYELL IMMUNOPHARMA, INC.
  • 16.2.5 KYVERNA THERAPEUTICS, INC.
  • 16.2.6 CELLICTIS SA
  • 16.2.7 BRAINCHILD BIO
  • 16.2.8 ATARA BIOTHERAPEUTICS, INC.
  • 16.2.9 CARIBOU BIOSCIENCES
  • 16.2.10 ARCELLX
  • 16.2.11 CRISPR THERAPEUTICS
  • 16.2.12 POSEIDA THERAPEUTICS
  • 16.2.13 CABALETTA BIO

17 RESEARCH METHODOLOGY

• 17.1 RESEARCH DATA
  • 17.1.1 SECONDARY DATA
    • 17.1.1.1 Objectives of secondary research
  • 17.1.2 PRIMARY DATA
    • 17.1.2.1 Breakdown of primaries
    • 17.1.2.2 Objectives of primary research
• 17.2 MARKET SIZE ESTIMATION
  • 17.2.1 BOTTOM-UP APPROACH
  • 17.2.2 INSIGHTS FROM PRIMARY EXPERTS
  • 17.2.3 SEGMENTAL MARKET SIZE ESTIMATION
• 17.3 GROWTH RATE ASSUMPTIONS
  • 17.3.1 CAGR PROJECTIONS
  • 17.3.2 IMPACT OF SUPPLY- AND DEMAND-SIDE FACTORS
• 17.4 DATA TRIANGULATION
• 17.5 RESEARCH LIMITATIONS
• 17.6 STUDY ASSUMPTIONS
• 17.7 RISK ANALYSIS

18 APPENDIX

• 18.1 DISCUSSION GUIDE
• 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 18.3 CUSTOMIZATION OPTIONS
• 18.4 RELATED REPORTS
• 18.5 AUTHOR DETAILS